Lenmeldy (atidarsagene autotemcel) - MEDICAID - FLORIDA

This policy covers Lenmeldy (atidarsagene autotemcel), an autologous hematopoietic stem cell–based gene therapy for metachromatic leukodystrophy (MLD) in children, specifically for presymptomatic late‑infantile (PSLI), presymptomatic early‑juvenile (PSEJ) and early symptomatic early‑juvenile (ESEJ) MLD associated with pathogenic ARSA mutations and ARSA deficiency. Coverage is limited to those prespecified pediatric MLD subtypes and requires medical director review with referral to the Corporate Transplant Department; it does not authorize use outside the listed indications.

"Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine."

Sign up to see full coverage criteria, indications, and limitations.